New Delhi : Country’s drug controller General of India (DCGI) has written a strongly worded letter to Rogerio Gaspar, Director, Regulation and Prequalification, WHO informing that all control samples of the products have been found to be complying with specifications. Government’s Central Drug Laboratory (CDL) which conducted quality tests on the samples lifted from Maiden pharmaceuticals – the Sonepat-based company which has been in the dock for allegedly causing deaths of children in Gambia has found the products to be complying with specifications, putting the onus on World Health Organisation (WHO) for “prematurely” blaming an Indian company for the deaths without any “independent verification”.
DGCI finds no violation in Maiden Pharma case as claimed by WHO
Membership
Doctors Post is a news portal tailored to provide current news & updates on issues related exclusively to medical & healthcare professionals. The content of Doctor Post is judiciously authored by a dedicated team of legal experts, doctors and reporters. The intent of the content is to expeditiously update doctor’s information & news necessary for the smooth functioning of their profession.
© 2024 Doctor Post. All Rights Reserved. Created and Maintained by Creative web Solution
Disclaimer: Use of the site is governed by our terms of use, privacy policy, and advertisement policy. For further details, please refer to our Disclaimer.